Roberto Da

1.7k citations

65 papers · 747 indexed · h-index 18

Impact in

Applied Microbiology and Biotechnology top 5%
- Antibiotic Use and Resistance
Toxicology top 5%

Papers in ⓘ

Applied Microbiology and Biotechnology 8
- Antibiotic Use and Resistance 8
Geriatrics and Gerontology 6
- Pharmaceutical Practices and Patient Outcomes 6

Co-authors: Francesca Menniti‐Ippolito (17 shared papers)Giuseppe Traversa (17 shared papers)Roberto Raschetti (11 shared papers)Stefania Spila Alegiani (17 shared papers)Francesco Trotta (17 shared papers)Luca Lorenzoni (3 shared papers)G. Traversa (8 shared papers)Gabriela Mazzanti (2 shared papers)
Journals: PLoS ONE (5 papers)BMJ Open (4 papers)Neurological Sciences (3 papers)British Journal of Clinical Pharmacology (3 papers)European Journal of Clinical Pharmacology (3 papers)
Partner nations: Italy United States Armenia

In The Last Decade

Roberto Da

63 papers receiving 727 citations

Peers

Countries citing papers authored by Roberto Da

Since Specialization

Citations

This map shows the geographic impact of Roberto Da's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Da with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Da more than expected).

Fields of papers citing papers by Roberto Da

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Da. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Da. The network helps show where Roberto Da may publish in the future.

Co-authors

The 25 scholars most cited alongside Roberto Da, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Roberto Da Line = papers co-authored together Roberto Da links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 65 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system British Journal of Clinical Pharmacology ·Gabriela Mazzanti, Paola Angela Moro, Emanuel Raschi, Roberto Da, Francesca Menniti‐Ippolito	2017	60
2	Association between Drug and Vaccine Use and Acute Immune Thrombocytopenia in Childhood Drug Safety ·Federica Bertuola, Carla Morando, Francesca Menniti‐Ippolito, Roberto Da, Annalisa Capuano, Giorgio Perilongo, Liviana Da Dalt	2009	39
3	The quality of abstracting medical information from the medical record: the impact of training programmes International Journal for Quality in Health Care ·Luca Lorenzoni, Roberto Da, Ugo Luigi Aparo	1999	36
4	Evaluation of safety of A/H1N1 pandemic vaccination during pregnancy: cohort study BMJ ·Francesco Trotta, Roberto Da, Stefania Spila Alegiani, Maria Gramegna, Mauro Venegoni, Carlo Zocchetti, G. Traversa	2014	36
5	Memantine effects on behaviour in moderately severe to severe Alzheimer’s disease: a post-marketing surveillance study Neurological Sciences ·(unknown), Francesca Clerici, Nicola Vanacore, Antonietta Elia, Stefania Spila Alegiani, Simone Pomati, Roberto Da, Roberto Raschetti, Claudio Mariani	2011	32
6	Ketorolac use in outpatients and gastrointestinal hospitalization: a comparison with other non-steroidal anti-inflammatory drugs in Italy European Journal of Clinical Pharmacology ·Francesca Menniti‐Ippolito, M. Maggini, Roberto Raschetti, Roberto Da, G. Traversa, A M Walker	1998	30
7	Gangliosides and Guillain-Barré syndrome Journal of Clinical Epidemiology ·Roberto Raschetti, M. Maggini, Patrizia Popoli, Bruno Caffari, Roberto Da, Francesca Menniti‐Ippolito, Stefania Spila Alegiani, G. Traversa	1995	25
8	Stevens-Johnson Syndrome Associated with Drugs and Vaccines in Children: A Case-Control Study PLoS ONE ·Umberto Raucci, Rossella Rossi, Roberto Da, Concetta Rafaniello, Nadia Mores, Giulia Bersani, Antonino Reale, Nicola Pirozzi, Francesca Menniti‐Ippolito, Giuseppe Traversa	2013	25
9	Drug use and acute leukemia Pharmacoepidemiology and Drug Safety ·Giuseppe Traversa, Francesca Menniti‐Ippolito, Roberto Da, Alfonso Mele, Alessandro Pulsoni, Franco Mandelli	1998	24
10	Henoch-Schönlein purpura and drug and vaccine use in childhood: a case-control study The Italian Journal of Pediatrics/Italian journal of pediatrics ·Liviana Da Dalt, Claudia Zerbinati, Maria Stefania Strafella, Salvatore Renna, Laura Riceputi, Pasquale Di Pietro, Paola Barabino, Stefania Scanferla, Umberto Raucci, Nadia Mores, Adele Compagnone, Roberto Da, Francesca Menniti‐Ippolito	2016	24
11	Monitoring the community use of antibiotics in Italy within the National Action Plan on antimicrobial resistance British Journal of Clinical Pharmacology ·Agnese Cangini, Filomena Fortinguerra, Aurora Di Filippo, Andrea Pierantozzi, Roberto Da, Federico Villa, Francesco Trotta, Maria Luisa Moro, Carlo Gagliotti	2020	23
12	The impact of Regional co-payment and National reimbursement criteria on statins use in Italy: an interrupted time-series analysis BMC Health Services Research ·Gianfranco Damiani, Bruno Federico, Angela Anselmi, Caterina Bianca Neve Aurora Bianchi, Giulia Silvestrini, Lanfranco Iodice, Pierluigi Navarra, Roberto Da, Roberto Raschetti, Walter Ricciardi	2014	20
13	Triptan use in Italy: Insights from administrative databases Cephalalgia ·Roberto Da, Anna Nigro, Salvatore Terrazzino, Grazia Sances, Michele Viana, Cristina Tassorelli, Giuseppe Nappi, Sarah Cargnin, Alessia Pisterna, Giuseppe Traversa, Armando A. Genazzani	2014	20
14	The cerivastatin withdrawal crisis: a “post-mortem” analysis Health Policy ·Marina Maggini, Roberto Raschetti, Giuseppe Traversa, C Bianchi, Bruno Caffari, Roberto Da, Pietro Panei	2004	20
15	Psychotropic drug use in Italy, 1984-99: the impact of a change in reimbursement status International Clinical Psychopharmacology ·Corrado Barbui, Annalisa Campomori, Luigi Mezzalira, Stefania Lopatriello, Roberto Da, Silvio Garattini	2001	20
16	Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021 Eurosurveillance ·Alberto Mateo‐Urdiales, Stefania Spila Alegiani, Massimo Fabiani, Patrizio Pezzotti, Antonietta Filia, Marco Massari, Flavia Riccardo, Marco Tallon, Valeria Proietti, Martina Del Manso, Maria Puopolo, Matteo Spuri, Cristina Morciano, Fortunato D’Ancona, Roberto Da, Serena Battilomo, Antonino Bella, Francesca Menniti‐Ippolito, (unknown), (unknown)	2021	20
17	The way forward in Italy for iodine Minerva Medica ·Antonella Olivieri, (unknown), Caterina Di Cosmo, Simona De Angelis, Roberto Da, Paolo Stacchini, Augusto Alberto Pastorelli, Paolo Vitti	2017	19
18	Adverse events following cannabis for medical use in Tuscany: An analysis of the Italian Phytovigilance database British Journal of Clinical Pharmacology ·Giada Crescioli, Niccolò Lombardi, Alessandra Bettiol, Francesca Menniti‐Ippolito, Roberto Da, M Parrilli, Martina Del Lungo, Eugenia Gallo, Alessandro Mugelli, Valentina Maggini, Fabio Firenzuoli, Alfredo Vannacci	2019	18
19	Memantine in Moderately-Severe-to-Severe Alzheimerʼs Disease Drugs & Aging ·Francesca Clerici, Nicola Vanacore, Antonietta Elia, Stefania Spila Alegiani, Simone Pomati, Roberto Da, Roberto Raschetti, Claudio Mariani	2009	17
20	Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy BMJ Open ·Francesco Trotta, Flávia Mayer, Francesco Barone‐Adesi, Immacolata Esposito, Ranadhir Reddy Punreddy, Roberto Da, Giuseppe Traversa, Francesco Perrone, Nello Martini, Bishal Gyawali, Antonio Addis	2019	17

About Roberto Da

Roberto Da is a scholar working on Applied Microbiology and Biotechnology, Geriatrics and Gerontology, Pharmacology, Molecular Medicine and Infectious Diseases, having authored 65 papers that have together received 747 indexed citations. Recurring topics across this work include Pharmaceutical Economics and Policy (9 papers), Antibiotic Use and Resistance (8 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers), Pharmaceutical Practices and Patient Outcomes (6 papers), Tuberculosis Research and Epidemiology (5 papers), SARS-CoV-2 and COVID-19 Research (5 papers), Drug-Induced Adverse Reactions (4 papers) and Vaccine Coverage and Hesitancy (3 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (37 citations), Toxicology (36 citations), Geriatrics and Gerontology (39 citations), Pharmacology (138 citations) and Medical Terminology (2 citations). Roberto Da has collaborated with scholars based in Italy, United States and Armenia. Frequent co-authors include Francesca Menniti‐Ippolito, Giuseppe Traversa, Roberto Raschetti, Stefania Spila Alegiani, Francesco Trotta, Luca Lorenzoni, G. Traversa, Gabriela Mazzanti, Paola Angela Moro and Emanuel Raschi. Their work appears in journals such as PLoS ONE, BMJ Open, Neurological Sciences, British Journal of Clinical Pharmacology and European Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact